<DOC>
	<DOCNO>NCT00820417</DOCNO>
	<brief_summary>This open-label , phase 1 , non-randomised , non-controlled trial , carry two centre patient advance cancer express EGFR . Primary objective determination maximum tolerate dose ( MTD ) recommend dose ( RD ) combination intravenous Cetuximab oral Gefitinib .</brief_summary>
	<brief_title>Pharmocokinetic/Pharmacodynamic ( PK/PD ) Study Combination Cetuximab/Gefitinib</brief_title>
	<detailed_description>Between 36 66 patient enrol depend number dose level complete . Patients histologically confirm EFGR-expressing solid malignant tumour ( colorectal cancer , head neck cancer NSCLC ) , respond standard therapy suitable therapy exists .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Written inform consent prior inclusion Confirmed histological diagnosis nonresectable , solid , malignant , EGFR express tumour follow type : colorectal cancer , head neck cancer nonsmall cell lung cancer ( NSCLC ) . Advanced clinical stage III/IV respond standard therapy suitable therapy exist Patients least one evaluable lesion ( evaluable disease ) RECIST criterion Availability tumour tissue , whether primary tumour metastasis determine EGFR expression Viability establish outpatient treatment Effective contraception patient sex risk conception Karnofsky performance status great 70 % Life expectancy &gt; 12 week Adequate renal function ( creatinine &lt; 1.5 x UNL ) , liver function ( bilirubin &lt; 1.5 x UNL , ALT/AST &lt; 2.5 x UNL &lt; 5 x UNL hepatic metastasis ) adequate bone marrow ( leucocytes &gt; 3000/µl , absolute neutrophil count &gt; 1500/µl , platelet &gt; 100,000/µl , haemoglobin &gt; 9 g/dl ) Patients must undergo chemotherapy , radiotherapy major surgery 3 week begin study , must recover relevant secondary effect previous treatment Patients agree new biopsy two week . Patients symptom bowel obstruction and/or inflammatory bowel disease Previous therapy antiEGFR drug Patients know cerebral metastasis Patients know active uncontrolled infection Severe uncontrolled organic dysfunction metabolic disorder Patients unable give inform consent Patients wish undergo specific study treatment study procedure Pregnancy breastfeed Patient participation another clinical trial previous 30 day Patients known drug and/or alcohol abuse Known hypersensitivity chimeric MoAbs pretreatment MoAbs Any malignant tumour last two year previously diagnose malignant tumour guarantee complete control , except suitably treat situ cervical carcinoma basocellular carcinoma Known severe hypersensitivity ZD1839 excipients product Any evidence clinically active interstitial lung disease ( patient chronic , stable , radiographic change asymptomatic need exclude ) Any unresolved chronic toxicity great common toxicity criterion ( CTC ) grade 2 previous anticancer therapy Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St John 's Wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>monoclonal</keyword>
	<keyword>antibody</keyword>
	<keyword>epidermal</keyword>
	<keyword>growth</keyword>
	<keyword>factor</keyword>
	<keyword>receptor</keyword>
	<keyword>EGFR</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>tyrosine</keyword>
	<keyword>kinase</keyword>
	<keyword>inhibitor</keyword>
	<keyword>advanced</keyword>
	<keyword>cancer</keyword>
</DOC>